A study to understand more about non Hodgkin lymphoma of the central nervous system and the testicles

Cancer type:

High grade lymphoma
Low grade lymphoma
Lymphoma
Non-Hodgkin lymphoma

Status:

Results

Phase:

Other

This study looked at samples from people with non Hodgkin lymphoma that started in either the brain, the spinal cord (the central nervous system), or the testicles (testes Open a glossary item), to learn more about these cancer cells.

Doctors wanted to find out why these cells behave abnormally. People gave a blood sample and permission for researchers to study other samples already given as part of routine care. They looked for the ‘immunoglobulin gene’, which helps the cancer cell to survive. They hoped that this research would help develop new treatments for these conditions in future. The aims of this study were to understand more about

  • The lymphoma cells, and why they behave in an unusual way
  • The immunoglobulin gene, and how it helps the lymphoma cells to survive

 

Summary of results

We have contacted the trial team who tell us they don’t expect to be making results available for this trial.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Christian Ottensmeier

Supported by

Experimental Cancer Medicine Centre (ECMC)
Tenovus
University Hospital Southampton NHS Foundation Trust

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 1616

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think